wide variety of cancers,” stated Dr. Olszanski. MEDI4736 is currently being evaluated further as monotherapy and in combination with a variety of immunomodulators and targeted agents. Dr. Olszanski has disclosed that he has served as a
Search Results
Principles of Immunotherapy
Anthony J. Olszanski
Novel Treatment Options for Neuroendocrine Tumors
Matthew H. Kulke
E2211 is an ongoing randomized study in patients with advanced panNETs evaluating temozolomide alone versus combination temozolomide and capecitabine. 3 Molecularly targeted agents also play an important role in the management of advanced panNETs
The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions
Toni K. Choueiri and Robert J. Motzer
at poor risk and with sarcomatoid histology. Similarly to nivolumab, the drug was well tolerated. 13 Studies of combination strategies with PD-1 and PD-L1 inhibitors and targeted agents are ongoing. 9 Another combination strategy involves a dual
Monitoring Response to Tyrosine Kinase Inhibitor Therapy, Mutational Analysis, and New Treatment Options in Chronic Myelogenous Leukemia
Jerald P. Radich
Fred Hutchinson Cancer Research Center in Seattle, Washington, and a member of the CML Panel of the NCCN. A “spectacular” difference has been seen in survival in early-phase CML with the targeted agents. 1 In his presentation at the NCCN 18th Annual
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
Shumei Kato, Vivek Subbiah, and Razelle Kurzrock
actionable molecular targets have emerged. There are currently >70 targeted agents FDA approved for the treatment of solid and hematologic malignancies, and the numbers continue to increase ( http
Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?
P. Connor Johnson
prephase steroids, given alone, with rituximab, or with vincristine, improve performance status and reduce infectious complications. 10 , 11 However, additional supportive care interventions and novel prephase regimens, perhaps using targeted agents or
The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors
Renuka Iyer and Kaunteya Reddy
. Therapy PNET Therapy Before 2011 Before the discovery of molecular targeted agents, the mainstay of treatment for NETs was initial debulking surgery for early-stage disease and a wide spectrum of options, from observation to locoregional therapy or a
The Abu Dhabi Declaration: Why the Hustle?
Hamdy A. Azim, Abdul-Rahman Jazieh, and Mohammad Jahanzeb
HA Azim HA Jr. Review article optimizing the use of her-2/neu targeting agents in breast cancer: a developing nation perspective . J Egypt Natl Canc Inst 2007 ; 19 : 225 – 230 .
Updates in Treatment Strategies for Hodgkin Lymphoma
Ranjana H. Advani
of 96%. Finally, given the success of the BV/nivolumab combination, investigators are even exploring the addition of another checkpoint inhibitor, ipilimumab, which targets CTLA-4. Regarding the combination of multiple targeted agents, “in a very
Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?
Tianhong Li
. Selaru P , Tang Y , Huang B , . Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib . Clin Transl Sci 2016 ; 9 : 63